Information  X 
Enter a valid email address

Benchmark Hlgs PLC (BMK)

  Print   

Tuesday 19 July, 2016

Benchmark Hlgs PLC

New Seabass Vaccine Commences Field Trials

RNS Number : 5178E
Benchmark Holdings PLC
19 July 2016
 

RNS Reach

19 July 2016

 

Benchmark Holdings plc

("Benchmark" or the "Group")

 

Benchmark's new seabass vaccine commences commercial field trials

 

Benchmark is pleased to announce that one of its new generation aquaculture vaccines has been released into the market for commercial field trials. The vaccine is the first in a series of Benchmark's new vaccines targeted at the €300m Mediterranean seabass market and aims to provide producers with an effective control of Nodavirus - a disease that impedes growth and causes high production losses. There was previously no effective treatment available for this endemic disease.

 

The trials will see a significant number of leading producers use the new vaccine 'on-farm' at commercial scale ahead of market authorisation, a process which typically takes 9 to 12 months.

 

Full development of the product has been undertaken in-house through exploiting the Group's R&D expertise, vaccine manufacturing capability and aquaculture trials facilities to ensure a streamlined and secure development process.

 

Nodavirus also affects several other farmed aquaculture species including Turbot, Barramundi and Grouper, and Benchmark now plans to provide these sectors with a similar solution. The development process for producing this vaccine for seabass can now be readily adapted to bring forward vaccines for these other species.

 

 

Malcolm Pye, Benchmark's CEO commented:

"This is another key milestone for Benchmark and is testament to our increased capability, as we continue to invest in our manufacturing capacity and technology, to open up new markets for the company by solving major challenges for our customers. This product represents a significant first for the Company, as the full development process including research, design, development and manufacturing, has been delivered entirely in-house by our specialist teams."

 

-ENDS-

 

 

 

For further information, please contact:

 

 

Benchmark Holdings plc

Tel:  020 7920 3150

Malcolm Pye, CEO

 

Roland Bonney, COO

 

Mark Plampin, CFO

 

Rachel Aninakwah, Communications

Tel: 018 6579 0880

 

 

Numis

Tel:  020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

 

James Black / Tom Ballard (Corporate Broking)

 

 

 

Tavistock

Tel:  020 7920 3150

Matt Ridsdale / Niall Walsh

 

 

 

 

 

Notes to Editors:

 

Founded in 2000, Benchmark represents a new model in sustainable business development. Over the last decade it has built a profitable group of companies on the economics of a sustainable food chain. The Company is growing in response to a rapidly increasing demand for sustainable food chains, and in particular for seafood, from both mature and emerging markets.

 

Benchmark is an ethical company with an explicit policy based on the "3E's" definition of a sustainable business - ethics, environment and economics - which guides its strategy and operations.

 

The Group has five divisions: Animal Health which researches, manufactures and markets medicines and vaccines particularly for aquaculture, Sustainable Science which researches and informs sustainable development in the food industry, Technical Publishing which effects technology transfer through online publishing and education, Breeding & Genetics which comprises a world-leading Salmon and aquaculture breeding business, and Advanced Animal Nutrition which provides cutting edge nutritional products and services to the aquaculture industry. Benchmark operates internationally with offices in England, Scotland, Belgium, Ireland, Norway, Iceland, USA, Brazil, China, Moscow, India, Thailand and Chile.  As at 30 June 2016, Benchmark employs 889 people.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRARPMFTMBMBBJF

a d v e r t i s e m e n t